No exemption or approval is required. Before dispensing methadone or buprenorphine-naloxone, review the OAT Guidelines and become familiar with relevant clinical guidelines, federal guidelines, and local programs. As of May , Health Canada no longer requires methadone prescribers to obtain a federal exemption under section 56 of the Controlled Drugs and Substances Act , and that oversight now lies with the various provincial regulators. Current exemptions in place are still active but will need to be renewed as they expire.
When pharmacists receive a prescription for methadone from an Alberta physician, they should direct all confirmation requests to CPSA at or or email methadoneinfo cpsa. Rather, they must complete education and preceptorship appropriate to the area of their prescribing and need only submit proof of this to CARNA upon their request. If the prescriber is licensed and does not have a condition on their licence restricting them from prescribing controlled drugs and substances, the pharmacist can dispense the medication.
Remember me. I forgot my password. Why sign up? Create Account. Suggest an Edit. Enter your suggested edit s to this article in the form field below.
Accessed 14 January In The Canadian Encyclopedia. Historica Canada. This edition of Full Scale introduces you to the OAT guidelines, explains what is different, indicates how to use the guidelines in conjunction with trusted clinical guidelines, and describes the person-centred approach and language. Full Scale also offers first-person accounts of the opioid crisis from people with lived experience, explores why the opioid crisis should be considered a public health crisis, and provides resources to help you further your understanding of this important health condition.
She also assisted with updating the guidelines based on her experience in the emergency room as a member of the health care team. In the development of the guidelines, subject matter experts including pharmacists, pharmacy technicians, physicians, nurses, harm reduction agencies, persons with lived experience, and family members with lived experience were all consulted and provided feedback.
Brett believes this input was crucial. Tiana feels the wide range of reviewers with differing areas of expertise means the guidelines are thorough. The guidelines are separated into part A and part B. Part A focuses on person-centred care. It will help regulated members understand the concepts of stigma, trauma-informed care, and harm reduction, and develop and maintain the proper perspective when reading the guidelines and providing patient care.
Incorporating these concepts into practice is integral to providing comprehensive care for individuals with substance use disorders. Part B lists the guidelines for pharmacists and pharmacy technicians providing care for patients using opioid agonist therapy. The language used in the guidelines was also updated.
0コメント